Arena licenses shelved insomnia treatment nelotanserin to Roivant; later discontinues development
Executive Summary
Roivant Sciences Ltd. received exclusive global development and commercialization rights to Arena Pharmaceuticals GMBH's serotonin 5-HT2A inverse agonist nelotanserin (formerly APD125).
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice